Details
Stereochemistry | RACEMIC |
Molecular Formula | C10H15NO2 |
Molecular Weight | 181.232 |
Optical Activity | ( + / - ) |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CCNCC(c1cccc(c1)O)O
InChI
InChIKey=SQVIAVUSQAWMKL-UHFFFAOYSA-N
InChI=1S/C10H15NO2/c1-2-11-7-10(13)8-4-3-5-9(12)6-8/h3-6,10-13H,2,7H2,1H3
Molecular Formula | C10H15NO2 |
Molecular Weight | 181.232 |
Charge | 0 |
Count |
|
Stereochemistry | RACEMIC |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Optical Activity | ( + / - ) |
DescriptionSources: https://www.sopharma.com/etilefrine.phpCurator's Comment:: description was created based on several sources, including
http://www.ncbi.nlm.nih.gov/pubmed/26240886
https://en.wikipedia.org/wiki/Etilefrin
Sources: https://www.sopharma.com/etilefrine.php
Curator's Comment:: description was created based on several sources, including
http://www.ncbi.nlm.nih.gov/pubmed/26240886
https://en.wikipedia.org/wiki/Etilefrin
Etilefrine is a cardiac stimulant used as an antihypotensive. Intravenous infusion of this compound increases cardiac output, stroke volume, venous return and blood pressure in man and experimental animals, suggesting stimulation of both α and β adrenergic receptors. However, in vitro studies indicate that etilefrine has a much higher affinity for β1 (cardiac) than for β2 adrenoreceptors. Intravenous etilefrine increases the pulse rate, cardiac output, stroke volume, central venous pressure and mean arterial pressure of healthy individuals. Marked falls in pulse rate, cardiac output, stroke volume and peripheral bloodflow, accompanied by rises in mean arterial pressure, occur when etilefrine is infused after administration of intravenous propranolol 2,5 mg. These findings indicate that etilefrine has both β1 and α1 adrenergic effects in man. The French Health Products Agency concluded that etilefrine and heptaminol have an unfavourable harm-benefit balance, and also placed restrictions on the use of midodrine.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL210 Sources: http://www.ncbi.nlm.nih.gov/pubmed/4790080 |
|||
Target ID: CHEMBL213 Sources: http://www.ncbi.nlm.nih.gov/pubmed/4790080 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Preventing | Unknown Approved UseUnknown |
|||
Sources: http://www.ncbi.nlm.nih.gov/pubmed/12181066 |
Preventing | Unknown Approved UseUnknown |
PubMed
Title | Date | PubMed |
---|---|---|
Etilefrine in the treatment of levodopa-induced orthostatic hypotension. | 1973 Aug |
|
Effect of selected drugs on arterial pressure response to upright posture. | 1976 |
|
Alfentanil combined with vecuronium or pancuronium: haemodynamic implications. | 1992 Jul |
|
[Ambulatory treatment and prevention of priapism using alpha-agonists. Apropos of 172 cases]. | 1997 Jan |
|
Effect of midodrine on chlorpromazine-induced orthostatic hypotension in rabbits: comparison with amezinium, etilefrine and droxidopa. | 2000 Dec |
|
Effects of hypertonic 75 mg/ml (7.5%) saline on extracellular water volume when used for preloading before spinal anaesthesia. | 2001 Jul |
|
Management of sickle cell priapism with etilefrine. | 2001 Jul |
|
Randomized clinical trials of neurally mediated syncope. | 2003 Sep |
|
Etilefrine use in the management of post-operative chyle leaks in thoracic surgery. | 2004 Mar |
|
[Efficacy and safety of a herbal drug containing hawthorn berries and D-camphor in hypotension and orthostatic circulatory disorders/results of a retrospective epidemiologic cohort study]. | 2005 |
|
Drug specificity and intestinal membrane localization of human organic cation transporters (OCT). | 2005 Dec 5 |
|
Indications, surgical technique, and long-term experience with laparoscopic closure of the nephrosplenic space in standing horses. | 2005 Nov-Dec |
|
[Management of postoperative chylothorax]. | 2006 Apr |
|
Clinical observations surrounding an increased incidence of postanesthetic myopathy in halothane-anesthetized horses. | 2006 Mar |
|
Anaesthesia with remifentanil infusion in diabetic versus non-diabetic patients undergoing vitrectomy. A Holter-controlled study. | 2007 |
|
Dissociation between cortical activation and cognitive performance under pharmacological blood pressure elevation in chronic hypotension. | 2007 Jul |
|
Development and validation of a liquid chromatography-tandem mass spectrometry method for the determination of phenylephrine in human plasma and its application to a pharmacokinetic study. | 2007 Oct 15 |
|
Stuttering priapism--a review of the therapeutic options. | 2008 Aug |
|
Chylous ascites following radical nephrectomy: a case report. | 2008 Jan 11 |
|
From methylene blue (methylthionine chloride) to Al-Ghorab procedure: the therapy of priapism (our experience). | 2009 Dec |
|
alpha-Adrenoceptor agonists for the treatment of vasovagal syncope: a meta-analysis of worldwide published data. | 2009 Jul |
|
Etilefrinhydrochloride tablet ingestion: successful therapy by endoscopic removal of tablet conglomerate. | 2009 Mar-Apr |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: http://www.ncbi.nlm.nih.gov/pubmed/10758467
15 mg (30 drops)
Route of Administration:
Oral
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Jun 26 03:09:59 UTC 2021
by
admin
on
Sat Jun 26 03:09:59 UTC 2021
|
Record UNII |
ZB6F8MY53V
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Systematic Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
WHO-VATC |
QC01CA51
Created by
admin on Sat Jun 26 03:09:59 UTC 2021 , Edited by admin on Sat Jun 26 03:09:59 UTC 2021
|
||
|
WHO-VATC |
QC01CA01
Created by
admin on Sat Jun 26 03:09:59 UTC 2021 , Edited by admin on Sat Jun 26 03:09:59 UTC 2021
|
||
|
EU-Orphan Drug |
EU/3/02/122
Created by
admin on Sat Jun 26 03:09:59 UTC 2021 , Edited by admin on Sat Jun 26 03:09:59 UTC 2021
|
||
|
NCI_THESAURUS |
C29747
Created by
admin on Sat Jun 26 03:09:59 UTC 2021 , Edited by admin on Sat Jun 26 03:09:59 UTC 2021
|
||
|
WHO-ATC |
C01CA01
Created by
admin on Sat Jun 26 03:09:59 UTC 2021 , Edited by admin on Sat Jun 26 03:09:59 UTC 2021
|
||
|
WHO-ATC |
C01CA51
Created by
admin on Sat Jun 26 03:09:59 UTC 2021 , Edited by admin on Sat Jun 26 03:09:59 UTC 2021
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
1101
Created by
admin on Sat Jun 26 03:09:59 UTC 2021 , Edited by admin on Sat Jun 26 03:09:59 UTC 2021
|
PRIMARY | |||
|
2229
Created by
admin on Sat Jun 26 03:09:59 UTC 2021 , Edited by admin on Sat Jun 26 03:09:59 UTC 2021
|
PRIMARY | |||
|
CHEMBL86882
Created by
admin on Sat Jun 26 03:09:59 UTC 2021 , Edited by admin on Sat Jun 26 03:09:59 UTC 2021
|
PRIMARY | |||
|
C65576
Created by
admin on Sat Jun 26 03:09:59 UTC 2021 , Edited by admin on Sat Jun 26 03:09:59 UTC 2021
|
PRIMARY | |||
|
10128-36-6
Created by
admin on Sat Jun 26 03:09:59 UTC 2021 , Edited by admin on Sat Jun 26 03:09:59 UTC 2021
|
SUPERSEDED | |||
|
DB08985
Created by
admin on Sat Jun 26 03:09:59 UTC 2021 , Edited by admin on Sat Jun 26 03:09:59 UTC 2021
|
PRIMARY | |||
|
SUB07303MIG
Created by
admin on Sat Jun 26 03:09:59 UTC 2021 , Edited by admin on Sat Jun 26 03:09:59 UTC 2021
|
PRIMARY | |||
|
M5184
Created by
admin on Sat Jun 26 03:09:59 UTC 2021 , Edited by admin on Sat Jun 26 03:09:59 UTC 2021
|
PRIMARY | Merck Index | ||
|
2409-85-0
Created by
admin on Sat Jun 26 03:09:59 UTC 2021 , Edited by admin on Sat Jun 26 03:09:59 UTC 2021
|
SUPERSEDED | |||
|
4169
Created by
admin on Sat Jun 26 03:09:59 UTC 2021 , Edited by admin on Sat Jun 26 03:09:59 UTC 2021
|
PRIMARY | RxNorm | ||
|
Etilefrine
Created by
admin on Sat Jun 26 03:09:59 UTC 2021 , Edited by admin on Sat Jun 26 03:09:59 UTC 2021
|
PRIMARY | |||
|
D005039
Created by
admin on Sat Jun 26 03:09:59 UTC 2021 , Edited by admin on Sat Jun 26 03:09:59 UTC 2021
|
PRIMARY | |||
|
ZB6F8MY53V
Created by
admin on Sat Jun 26 03:09:59 UTC 2021 , Edited by admin on Sat Jun 26 03:09:59 UTC 2021
|
PRIMARY | |||
|
709-55-7
Created by
admin on Sat Jun 26 03:09:59 UTC 2021 , Edited by admin on Sat Jun 26 03:09:59 UTC 2021
|
PRIMARY | |||
|
233-359-9
Created by
admin on Sat Jun 26 03:09:59 UTC 2021 , Edited by admin on Sat Jun 26 03:09:59 UTC 2021
|
ALTERNATIVE | |||
|
211-910-4
Created by
admin on Sat Jun 26 03:09:59 UTC 2021 , Edited by admin on Sat Jun 26 03:09:59 UTC 2021
|
PRIMARY | |||
|
709-55-7
Created by
admin on Sat Jun 26 03:09:59 UTC 2021 , Edited by admin on Sat Jun 26 03:09:59 UTC 2021
|
PRIMARY | |||
|
3306
Created by
admin on Sat Jun 26 03:09:59 UTC 2021 , Edited by admin on Sat Jun 26 03:09:59 UTC 2021
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
SALT/SOLVATE -> PARENT | |||
|
TRANSPORTER -> INHIBITOR | |||
|
ENANTIOMER -> RACEMATE | |||
|
TARGET -> AGONIST | |||
|
ENANTIOMER -> RACEMATE | |||
|
TRANSPORTER -> INHIBITOR |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |